The Rhythm | Issue 31
Issue 31 | Week of 2 November 2026
Transcatheter Cardiovascular Therapeutics (TCT) 2026 opened in San Diego on 31 October. This week's issue covers research published between 25 and 31 October, including a randomised trial featured at the meeting. TCT's major randomised results will follow in next week's issue.
Cardiology Intelligence Briefing: the proxy is not the patient
A faster test, a more natural heartbeat, an earlier start, a safer dose. Each promises better care, but the measure we improve is not always the outcome that matters. This week's evidence shows why.
Across five randomised trials, shortening the interval between troponin samples from three hours to one did not consistently reduce emergency department (ED) stays.1 The pooled result masked wide variation between hospitals, while uncertainty remained around the comparison of 30-day safety outcomes.1 By contrast, two randomised device trials, both from China, reported fewer clinical events, although neither demonstrated a survival benefit.2,3 Pacing through the heart's conduction system reduced heart failure events compared with conventional right ventricular pacing, while transcatheter treatment of severe aortic regurgitation reduced a composite outcome driven by fewer heart failure rehospitalisations, at the cost of more bleeding and pacemakers.2,3
Other findings challenge assumptions about safety and timing. High-dose intravenous loop diuretics caused transient hearing changes around peak drug concentration, but no clinically diagnosed ototoxicity was observed in two small prospective cohorts.4 In refractory cardiac arrest, a nationwide registry associated extracorporeal resuscitation with better survival even after prolonged ED resuscitation.5 Yet the analysis measured time from hospital arrival, not from the arrest itself, and cannot establish a causal benefit.5
The common lesson is not that faster tests, physiological pacing or new procedures lack value. It is that their value must be judged by what they deliver for patients, how convincingly that benefit has been demonstrated, and what risks accompany it.
